Homepage > Company > Media > Pharma News > 2018 > Clovis Oncology, execs to pay $20 million to settle SEC charges

Clovis Oncology, execs to pay $20 million to settle SEC charges

WASHINGTON (Reuters) - U.S. biotechnology company Clovis Oncology Inc and its Chief Executive Patrick Mahaffy and former CFO Erle Mast, will pay more than $20 million to settle charges of misleading investors about the efficacy of a cancer drug, the top U.S. securities regulator said on Tuesday.

The Securities and Exchange Commission said they agreed to the settlement without admitting or denying the allegations, and that the settlements are subject to court approval.

According to the SEC, Clovis continually told investors that its drug, Roci, caused targeted tumors to shrink in 60 percent of patients, when data showed it had actually caused tumor shrinkage in 42 percent of patients.

Once Clovis disclosed the true efficacy rate at the end of 2015, its stock price dropped about 70 percent, the SEC added.

SEPTEMBER 18, 2018

https://uk.reuters.com/

Read also

Phase 3 trials of treatment combo for hepatitis D expected in 2025

On the heels of positive Phase 2 clinical trial data, Vir Biotechnology is planning for the 2025 launch of a Phase 3 program, dubbed ECLIPSE, to test its treatment combination of tobevibart and elebsi...

Breakthrough Therapy Designation Market Is Booming Worldwide 2024-2032

The Breakthrough Therapy Designation market has witnessed significant growth over the past decade, driven by advancements in technology, shifting consumer preferences, and increasing investments from ...

Veeva Commercial Summit: Increased investment in medical affairs by pharma companies

Veeva’s VP of global medical, Christoph Bug, emphasises the importance of scientific exchange between clinical experts and pharmaceutical companies.

Remix

Remix Therapeutics to Present Preclinical Data Demonstrating Anti-Leukemic Activity of REM-422 in AML at the 66th American Society of Hematology Annual Meeting and Exposition (ASH)